Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Thomas William Flaig

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-0499

    Collapse Research 
    Collapse research activities and funding
    R21CA152375     (FLAIG, THOMAS W)Jul 1, 2010 - May 31, 2013
    NIH/NCI
    Targeted nanoparticle thermoablation for the treatment of bladder cancer
    Role: Principal Investigator

    UM1CA186688     (MERIC-BERNSTAM, FUNDA)Mar 14, 2014 - Feb 28, 2020
    NIH/NCI
    Southwest Early Clinical Trials Consortium
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct; 15(10):1240-1267. PMID: 28982750.
      View in: PubMed
    2. Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA. Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer. 2017 Jul 27; 3(3):211-223. PMID: 28824949.
      View in: PubMed
    3. Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 2017 Jul 27; 3(3):201-210. PMID: 28824948.
      View in: PubMed
    4. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017 Jun 01; 28(6):1339-1345. PMID: 28327953.
      View in: PubMed
    5. Flaig TW, Salzmann-Sullivan M, Su LJ, Zhang Z, Joshi M, Gijón MA, Kim J, Arcaroli JJ, Van Bokhoven A, Lucia MS, La Rosa FG, Schlaepfer IR. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 2017 Aug 22; 8(34):56051-56065. PMID: 28915573.
      View in: PubMed
    6. Flaig TW, Plets M, Hussain MH, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Mar 30. PMID: 28358937.
      View in: PubMed
    7. Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017 Oct; 15(5):610-617.e3. PMID: 28344102.
      View in: PubMed
    8. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun; 35(6):438-446. PMID: 28214281.
      View in: PubMed
    9. Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 Dec; 5(12):3386-3393. PMID: 27758076.
      View in: PubMed
    10. Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review? Urology. 2017 Apr; 102:7-16. PMID: 27769917.
      View in: PubMed
    11. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clin Genitourin Cancer. 2017 Apr; 15(2):273-279.e1. PMID: 27876504.
      View in: PubMed
    12. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct; 14(10):1213-1224. PMID: 27697976.
      View in: PubMed
    13. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 Apr; 71(4):656-664. PMID: 27402060.
      View in: PubMed
    14. Bourlon MT, Flaig TW. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. Curr Drug Targets. 2016; 17(2):196-205. PMID: 26044568.
      View in: PubMed
    15. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016 Feb; 5(2):182-91. PMID: 26710718; PMCID: PMC4735776.
    16. Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 12; 29(12):956-62. PMID: 26676900.
      View in: PubMed
    17. Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016 Apr; 27(4):699-705. PMID: 26609008.
      View in: PubMed
    18. Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb; 27(2):286-94. PMID: 26578735.
      View in: PubMed
    19. Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28; 10:218. PMID: 26510665; PMCID: PMC4625576.
    20. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015 04; 12(4):225-35. PMID: 25800393.
      View in: PubMed
    21. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. PMID: 25601341.
      View in: PubMed
    22. Bourlon MT, Flaig TW. Visceral metastases in prostate cancer: an underestimated and understudied subgroup. Oncology (Williston Park). 2014 Nov; 28(11):980-6. PMID: 25403630.
      View in: PubMed
    23. Bourlon MT, Amini A, Kavanagh BD, Flaig TW. Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapy. Oncology (Williston Park). 2014 Nov; 28(11):1008-12. PMID: 25560737.
      View in: PubMed
    24. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5. PMID: 25075565; PMCID: PMC4127096.
    25. Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2015 Feb; 33(2):71.e11-9. PMID: 25151595.
      View in: PubMed
    26. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64. PMID: 25065704.
      View in: PubMed
    27. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Sep 01; 32(25):2765-72. PMID: 25049330.
      View in: PubMed
    28. Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul; 10(7):1267-76. PMID: 24804547.
      View in: PubMed
    29. Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32. PMID: 24931270; PMCID: PMC4687398.
    30. Kessler ER, Flaig TW. Geriatric considerations in the treatment of advanced prostate cancer. F1000Prime Rep. 2014; 6:33. PMID: 24860655; PMCID: PMC4017909.
    31. Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC. Geriatric oncology for the 21st century: a call for action. J Oncol Pract. 2014 Jul; 10(4):241-3. PMID: 24781365.
      View in: PubMed
    32. Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014 Jul; 32(5):707-13. PMID: 24629494.
      View in: PubMed
    33. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231; PMCID: PMC4418928.
    34. Cost NG, Maroni P, Flaig TW. Metastatic relapse after initial clinical stage I testicular Leydig cell tumor. Oncology (Williston Park). 2014 Mar; 28(3):211, 214. PMID: 24855728.
      View in: PubMed
    35. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. PMID: 24829759; PMCID: PMC4019894.
    36. Kessler ER, Flaig TW. Sequencing medical therapy in prostate cancer: not as easy as 1-2-3. Oncology (Williston Park). 2013 Nov; 27(11):1158-60. PMID: 24575544.
      View in: PubMed
    37. Goodman OB, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):34-9. PMID: 24080993; PMCID: PMC3921671.
    38. Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One. 2013; 8(9):e74809. PMID: 24058630; PMCID: PMC3776760.
    39. Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park). 2013 Sep; 27(9):893, 896, 898. PMID: 24282987.
      View in: PubMed
    40. Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014 Jan; 13(1):46-53. PMID: 23757319; PMCID: PMC3866213.
    41. Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May; 49(5):303-15. PMID: 23724410.
      View in: PubMed
    42. Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol Surg. 2013 Jul; 39(7):981-7. PMID: 23464361.
      View in: PubMed
    43. Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park). 2013 Mar; 27(3):219-26. PMID: 23687793.
      View in: PubMed
    44. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172; PMCID: PMC3683570.
    45. Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2013 Jan; 10(1):41-51. PMID: 23183631.
      View in: PubMed
    46. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 01; 19(1):148-57. PMID: 23172881; PMCID: PMC3537889.
    47. Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012 Nov; 29(11):871-83. PMID: 23135826.
      View in: PubMed
    48. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44. PMID: 23110259.
      View in: PubMed
    49. Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012 Dec; 10(4):225-31. PMID: 23017335; PMCID: PMC3511908.
    50. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97. PMID: 22894553.
      View in: PubMed
    51. Flaig TW, Theodorescu D. Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. Eur Urol. 2012 Jul; 62(1):183-4. PMID: 22640860; PMCID: PMC4024709.
    52. Lam ET, Flaig TW. Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol. 2012 May 29; 9(7):358-60. PMID: 22641162.
      View in: PubMed
    53. Yang X, Bemis L, Su LJ, Gao D, Flaig TW. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. Biores Open Access. 2012 Apr; 1(2):55-62. PMID: 23514806; PMCID: PMC3559200.
    54. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25. PMID: 22415798.
      View in: PubMed
    55. Hou X, Flaig TW. Redefining hormone sensitive disease in advanced prostate cancer. Adv Urol. 2012; 2012:978531. PMID: 22461790; PMCID: PMC3296168.
    56. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urol Oncol. 2013 Oct; 31(7):968-73. PMID: 22300756.
      View in: PubMed
    57. Crawford ED, Flaig TW. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology (Williston Park). 2012 Jan; 26(1):70-7. PMID: 22393799.
      View in: PubMed
    58. Flaig TW, Theodorescu D. Bladder cancer in 2011: the dawn of personalized medicine. Nat Rev Urol. 2011 Dec 20; 9(2):65-6. PMID: 22187014; PMCID: PMC4020619.
    59. Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011 Oct; 78(4):863-7. PMID: 21813167; PMCID: PMC3190033.
    60. Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW. A rare case of metastatic renal epithelioid angiomyolipoma. Oncology (Williston Park). 2011 Aug; 25(9):832-8. PMID: 21936445.
      View in: PubMed
    61. Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 2013 Feb; 31(2):198-204. PMID: 21795073; PMCID: PMC3229833.
    62. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005. PMID: 21612468; PMCID: PMC3471149.
    63. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011 Jul; 78(1):233.e7-13. PMID: 21529900; PMCID: PMC3126899.
    64. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5. PMID: 21502546; PMCID: PMC3107759.
    65. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34. PMID: 21477295; PMCID: PMC3094365.
    66. Rove KO, Flaig TW. A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park). 2010 Dec; 24(14):1308-13, 1318. PMID: 21294475.
      View in: PubMed
    67. Sumey C, Flaig TW. Adjuvant medical therapy for prostate cancer. Expert Opin Pharmacother. 2011 Jan; 12(1):73-84. PMID: 21118060.
      View in: PubMed
    68. Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep. 2010 Oct; 24(4):1019-28. PMID: 20811684.
      View in: PubMed
    69. Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. 2010 Sep 07; 103(6):796-801. PMID: 20823888; PMCID: PMC2966634.
    70. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55. PMID: 20127732.
      View in: PubMed
    71. Yang X, Flaig TW. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol. 2010 May-Jun; 36(3):273-82. PMID: 20602819.
      View in: PubMed
    72. Flaig TW, Kondo KL, La Rosa FG, Kavanagh B, Crawford ED. A young woman with multiple kidney lesions. Oncology (Williston Park). 2010 Mar; 24(3):282-6. PMID: 20394141.
      View in: PubMed
    73. Siomos VJ, La Rosa FG, Flaig TW, Kondo KL, Mitchell JD, Wilson S, Barqawi AB. Recurrent urothelial carcinoma with pulmonary metastasis. Oncology (Williston Park). 2009 Dec; 23(14):1301-4. PMID: 20120845.
      View in: PubMed
    74. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37. PMID: 19220256.
      View in: PubMed
    75. Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S. A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma? Oncology (Williston Park). 2009 Feb; 23(2):177-80. PMID: 19323300.
      View in: PubMed
    76. Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res. 2009 Jan 01; 1(1):80-6. PMID: 19966941; PMCID: PMC2776293.
    77. Flaig TW, Glodé LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008 Nov; 9(16):2829-41. PMID: 18937615.
      View in: PubMed
    78. O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy. 2008 Aug; 28(8):1071-5. PMID: 18657023.
      View in: PubMed
    79. Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009 Feb; 27(1):83-7. PMID: 18563296.
      View in: PubMed
    80. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6. PMID: 18349405.
      View in: PubMed
    81. Rusthoven KE, Flaig TW, Raben D, Kavanagh BD. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials. Clin Lung Cancer. 2008 Mar; 9(2):106-11. PMID: 18501097.
      View in: PubMed
    82. La Rosa FG, Flaig TW, Wilson S, Crawford ED, Kim FJ. Sarcoidosis in a man with renal carcinoid tumor. Oncology (Williston Park). 2007 Nov; 21(13):1593-6. PMID: 18179048.
      View in: PubMed
    83. Flaig TW, Su LJ, Harrison G, Agarwal R, Glodé LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 01; 120(9):2028-33. PMID: 17230508.
      View in: PubMed
    84. Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F, Glodé LM. Prostate cancer in a man with multiple previous cancers. Oncology (Williston Park). 2007 Apr; 21(5):611-4. PMID: 17536345.
      View in: PubMed
    85. Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol. 2007 Apr; 177(4):1229-37. PMID: 17382696.
      View in: PubMed
    86. Arthur C, Flaig T, Su LJ, Denney R, Barnes F, Glodé LM. The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Ultrasonics. 2007 Mar; 46(1):68-73. PMID: 17173946.
      View in: PubMed
    87. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 Apr; 25(2):139-46. PMID: 17077998.
      View in: PubMed
    88. Bowles DW, Flaig TW. Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review. Cancer Invest. 2006 Aug-Sep; 24(5):517-20. PMID: 16939961.
      View in: PubMed
    89. Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006 Jul 15; 107(2):266-74. PMID: 16779800.
      View in: PubMed
    90. Saba N, Flaig T. Bone marrow transplantation for nonmalignant diseases. J Hematother Stem Cell Res. 2002 Apr; 11(2):377-87. PMID: 11983109.
      View in: PubMed
    Flaig's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)